about
Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.Intercentre variance in patient reported outcomes is lower than objective rheumatoid arthritis activity measures: a cross-sectional study.The non-silent epidemic: low back pain as a primary cause of hospitalisation.The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project).[Cognitive dysfunction in systemic lupus erythematosus in relation to disease activity and damage].[Effect of low doses of oral pamidronate (APD) on the calcemia of osteopenic or osteoporotic patients]The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA programSurvey on transportation and storage of biological therapies by patients[Oxidative cellular damage in the digestive system][Gastrointestinal involvement in progressive systemic sclerosis]Serum kinetics, bioavailability and bone scanning of 99mTc-labelled sodium olpadronate in patients with different rates of bone turnover[Giant duodenal diverticula with heterotopic gastric mucosa. Its demonstration with technetium 99][Lung cancer. Analysis of 240 cases][Colonic angiodysplasia: report of a case and considerations]A survey on the current evaluation and treatment of gout in Buenos Aires, ArgentinaUse of systemic glucocorticoids in patients with psoriatic arthritis by Argentinian and other Latin-American rheumatologistsDescription of the resources for rheumatology training and speciality certification and recertification requirements in Argentina
P50
Q37065115-B973EFCF-729E-40A1-AC0F-E5633DD52CABQ37404701-16C84D04-37AD-495E-81E3-AC6C34DEC424Q38748219-634F819E-0CF6-4EA5-B712-DB1A240AD85AQ40115796-42B51365-C863-42EB-87A1-12A55C3A1DBCQ47381622-70688D8F-A166-430A-9D30-9C8C781B685EQ50567234-B78A0A56-0CCA-43D6-9409-879D67B0044BQ54408072-5E1EE395-F328-45C7-9BBC-CEE65BE656BAQ56973963-6691E4A7-4F07-47DA-A283-BB9B00E5159DQ64091998-6C75DA15-79FF-496D-8987-D49A74E62E99Q68230055-C7F7C120-EBB6-404A-930D-161659085569Q70788345-EFF51B4A-06C4-4666-A70B-3E0056EECC8EQ70953559-6DC88037-B512-425B-98F3-D2F4285C934DQ71592999-2426C10A-98A7-47DA-90F6-2FB851669BDEQ71809362-2B78DFE4-DBE3-4A9F-A938-8041AC9EF91BQ72094034-F9C5C797-4C61-4194-9B18-3767404EBB27Q84702785-2E368D10-8D9A-4413-8E5D-DC825377D046Q92104446-72E01B89-4EB0-49F7-8060-C0924853E23EQ92367009-70F97A2E-B544-44F5-BBE7-45B03354C8CC
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Eduardo Kerzberg
@ast
Eduardo Kerzberg
@en
Eduardo Kerzberg
@es
Eduardo Kerzberg
@nl
type
label
Eduardo Kerzberg
@ast
Eduardo Kerzberg
@en
Eduardo Kerzberg
@es
Eduardo Kerzberg
@nl
prefLabel
Eduardo Kerzberg
@ast
Eduardo Kerzberg
@en
Eduardo Kerzberg
@es
Eduardo Kerzberg
@nl
P106
P21
P31
P496
0000-0002-5704-6777